Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cuiyu Guo

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Trends in Pharmacological Sciences|November 11, 2025
Artificial intelligence in antibody-drug conjugate developmentYuxi Wang, Cuiyu Guo, Weimin Li
European Journal of Medicinal Chemistry|May 31, 2024
Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatmentCuiyu Guo, Guangbing Zhang, Chengyong Wu, et al.
European Journal of Medicinal Chemistry|July 7, 2024
Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapyChengyong Wu, Lele Zhang, Zhilan Zhou, et al.
Protein Expression and Purification|October 10, 2021
Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factorShuang Liu, Yunlong Shen, Pengyu Chen, et al.
Journal of Drug Targeting|July 29, 2024
Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancerYiran Tao, Ying Lu, Ting Xue, et al.
European Journal of Medicinal Chemistry|October 31, 2025
Structure-guided design of potent tetrazolo[1,5-a]pyrimidine-based tubulin inhibitors with in vivo antitumor activityYaolin Guo, Quanwei Yu, Cuiyu Guo, et al.
Journal of Medicinal Chemistry|September 20, 2025
Discovery of Novel 4,5-Dihydropyrrolo[3,4-<i>c</i>]pyrazol-6(<i>2H</i>)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer ActivityQuanwei Yu, Yujie Liu, Zhijia Wang, et al.
International Journal of Cancer|January 5, 2024
Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapyYujia Peng, Yuyin Fu, Hong Liu, et al.
Medcomm|November 12, 2021
Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivoCuiyu Guo, E Dong, Qinhuai Lai, et al.
Molecular Oncology|May 23, 2019
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinomaYiran Tao, Ruixue Wang, Qinhuai Lai, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Trends in Pharmacological Sciences|November 11, 2025
Artificial intelligence in antibody-drug conjugate developmentYuxi Wang, Cuiyu Guo, Weimin Li
European Journal of Medicinal Chemistry|May 31, 2024
Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatmentCuiyu Guo, Guangbing Zhang, Chengyong Wu, et al.
European Journal of Medicinal Chemistry|July 7, 2024
Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapyChengyong Wu, Lele Zhang, Zhilan Zhou, et al.
Protein Expression and Purification|October 10, 2021
Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factorShuang Liu, Yunlong Shen, Pengyu Chen, et al.
Journal of Drug Targeting|July 29, 2024
Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancerYiran Tao, Ying Lu, Ting Xue, et al.
European Journal of Medicinal Chemistry|October 31, 2025
Structure-guided design of potent tetrazolo[1,5-a]pyrimidine-based tubulin inhibitors with in vivo antitumor activityYaolin Guo, Quanwei Yu, Cuiyu Guo, et al.
Journal of Medicinal Chemistry|September 20, 2025
Discovery of Novel 4,5-Dihydropyrrolo[3,4-<i>c</i>]pyrazol-6(<i>2H</i>)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer ActivityQuanwei Yu, Yujie Liu, Zhijia Wang, et al.
International Journal of Cancer|January 5, 2024
Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapyYujia Peng, Yuyin Fu, Hong Liu, et al.
Medcomm|November 12, 2021
Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivoCuiyu Guo, E Dong, Qinhuai Lai, et al.
Molecular Oncology|May 23, 2019
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinomaYiran Tao, Ruixue Wang, Qinhuai Lai, et al.
Pageof 2